Author

Yang Mao‐Draayer

Oklahoma Medical Research FoundationORCID 0000-0001-6248-3480Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Joshua S MytychiD· 2 shared Mirela CerghetiD· 2 shared Ramandeep RattaniD· 2 shared Shailendra GiriiD· 2 shared Christopher D. SchareriD· 1 shared David A. FoxiD· 1 shared Dean E. Draayer· 1 shared Deanna DwyeriD· 1 shared

Activity by Year

2023-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Joshua S MytychORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologyInternational Journal of Molecular SciencesPeer-reviewedMay 29, 2026

Longitudinal and stability-aware analysis reveals treatment-specific microRNA response signatures following immune-reconstitution and B-cell-targeted therapies in multiple sclerosis

Nasar Ata, Joshua S Mytych, Mirela Cerghet…·Yang Mao‐Draayer

This study identifies treatment-specific miRNA response signatures in RRMS patients following cladribine or ocrelizumab, revealing distinct molecular programs associated with each therapy.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky

ImmunologybioRxivPreprintMar 26, 2026

Ocrelizumab Modulates Both B and T Cell Immune Capacities in Multiple Sclerosis

Qi Wu, Mikel Gurrea‐Rubio, Q. Wang…·Yang Mao‐Draayer

This study examines how ocrelizumab affects B and T cell populations in MS patients, revealing changes in B cell subsets and T cell dynamics, along with altered signaling pathways.

DOI 10.64898/2026.03.24.713043

humanflow cytometry

𝕏 PostBluesky

ImmunologybioRxivPreprintSep 25, 2023

Maresin-1 promotes neuroprotection and prevents disease progression in experimental models of multiple sclerosis through metabolic reprogramming and shaping innate and adaptive disease-associated cell types

Insha Zahoor, Mohammad Nematullah, Mohammad Ejaz Ahmed…·Shailendra Giri

This study shows that MaR1 treatment reduces inflammation, protects neurons, and improves metabolism in a mouse model of multiple sclerosis.

2 citations

mouseexperimental assay

𝕏 PostBluesky